疫情冲击下，全球干细胞市场将发生怎样的变化？
2020-08-05
In 2020, the new crown epidemic has had an impact on many industries. However, this impact is diverse. For example, it may lead to a decline in demand in some industries, but it will also stimulate the stable or even faster development of some industries. Encouraging market growth opportunities, such as the epidemic has caused a higher growth rate in the medical industry.
Stem cell therapy, which is considered to have brought a new round of medical revolution, has shown broader application prospects during the epidemic, and many countries have successively launched clinical projects. The impact of the epidemic has brought new development opportunities to the global stem cell market. According to a report released by Technavio, a world-renowned research institution, the global stem cell therapy market is expected to grow by about US$580 million between 2020 and 2024, and is expected to grow at a compound annual growth rate of 7% [1].
The report pointed out that an important factor driving the growth of the global stem cell therapy market is the increasing awareness of stem cell therapy.
Middle and upper reaches: The compound annual growth rate of the stem cell storage market is nearly 10%
With the rising demand for personalized medicine in modern medicine, more and more people are storing stem cells for future treatment. According to the analysis of the international research organization MRFP[2], the compound annual growth rate of the global stem cell storage market from 2019 to 2025 is expected to be 9.8%, and it will exceed US$12 billion by 2025.
According to MRFP data, the global stem cell storage market can be divided into neonatal stem cells (umbilical cord blood, umbilical cord and placenta), adult stem cells and embryonic stem cells according to cell types. According to the analysis of MRFP, neonatal stem cells will maintain the highest market share during the forecast period.
This is similar to the results of the market research report released by Markets and Markets, the world's second largest market research and consulting company in 2018: In the global stem cell storage market, the placental stem cell market is expected to grow the fastest. This is mainly due to the increasing number of placenta and umbilical cord stores worldwide, and the increasing public awareness of the potential of stem cell therapy.
It can be seen that neonatal stem cell storage has become the mainstream of the stem cell storage market.
Downstream: The clinical demand for stem cells continues to increase
According to Technavio's data [1], the global stem cell therapy market was worth US$1.58 billion in 2019 and is expected to reach US$2.16 billion by 2024. The industry perspective in the stem cell market size analysis report (2019-2025) released by the American market research company GRAND VIEW RESEARCH has such a set of data: between 2005 and 2013, the number of diseases that can be treated by stem cells has increased by 300%. In the future, with the help of stem cell technology, the number of treatable diseases will continue to increase.
From the downstream clinical application, according to the classification of diseases, the global stem cell therapy market can be divided into thalassemia, cerebral palsy, diabetes, leukemia, autism, etc. Due to the increasing burden of diabetes worldwide, this application area may be the fastest growing part of the stem cell therapy market, thereby increasing the demand for stem cell therapy [2]. According to statistics released by the International Diabetes Federation, nearly 425 million adults worldwide had diabetes in 2017, and it is expected to increase to 629 million by 2025.
In recent years, the capital market has also favored stem cells to treat diabetes. In 2019, Forte Pharmaceuticals acquired the development of diabetes stem cell therapy for US$950 million. In 2018, ViaCyte, a diabetes regenerative medicine company in San Diego, USA, received more than US$100 million in financing. In 2017, American biotech cutting-edge Semima Therapeutics raised US$114 million for the development of Type I Stem cell therapy for diabetes.
At present, global companies engaged in the research and development of stem cell therapy for diabetes include Athersys, Mesoblast, Caladrius Biosciences, ViaCyte, Sernova, Eli Lilly, Sanofi, and Novo Nordisk, etc., and many products have entered the clinical trial stage, and more and more The closer to the market.
This shows that the downstream market for stem cell therapy will usher in greater opportunities in the future.
The whole industry: the global market value will reach 270 billion US dollars
The global stem cell market includes upper and midstream stem cell storage and preparation as well as downstream clinical applications. According to a report by Transparency Market Research, by the end of 2025, the global stem cell market is expected to reach 270.5 billion U.S. dollars, and the compound annual growth rate of the global stem cell market in the past eight years is expected to reach 13.8% [3].
The momentum will be very strong. In addition, factors driving the growth of the global stem cell market also include: increasing investment in stem cell research projects by biopharmaceuticals and pharmaceutical companies, rapid development of infrastructure required for stem cell storage and processing, increased awareness of stem cell treatment of diseases, and government Favorable supervision of stem cells, etc.
Stem cells are believed to create new opportunities for pharmaceutical companies. Just as in the field of diabetes, pharmaceutical giants such as Eli Lilly, Novo Nordisk, Sanofi, and start-ups have moved to the field of stem cells. Not only is it to develop new stem cell drugs, but pharmaceutical companies can also use stem cell technology to identify drug candidates to promote the development of new drugs. For example, induced pluripotent stem cells are used to develop organoids in human tissues as disease models for research and development of targeted drugs.
Outlook
In 2020, stem cell treatment of new coronary pneumonia has achieved phased results, demonstrating the infinite possibilities of stem cell therapy from the downstream application. At present, more than a dozen stem cell drugs have been approved for marketing in the world. The indications include knee cartilage defects, graft-versus-host disease, Crohn’s disease, acute myocardial infarction, inherited or acquired hematopoietic diseases, degenerative arthritis, Herler syndrome, moderate to severe limbal stem cell deficiency, and thrombotic arteritis obliterans. With the development of stem cell technology, the indications it targets will be more extensive, and the market prospects it will stimulate will also be broader.
